[HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs].
Fabio MazzaAngela CicciarelliFilomena RubinoFrancesca ApponiErnesto Anselmo CioffiRoberto SimonelliPublished in: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia (2024)
Roxadustat, recently approved, is a hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. This article reviews main features and possible effects by activation of pathway sequences HREs.